西黄胶囊联合醋酸甲羟孕酮对子宫内膜癌化疗患者预后及相关指标的影响

doi:10.3969/j.issn.1006-6233.2025.04.028

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1469 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effects of Xihuang capsules combined with medroxyprogesterone acetate on serum microRNA (miR)-146a, miR-155 levels, and prognosis in patients with endometrial cancer undergoing chemotherapy. Methods: A total of 132 patients with endometrial cancer undergoing chemotherapy from January 2019 to May 2022 were selected and randomly divided into two groups (n=66 per group). The control group received medroxyprogesterone acetate, while the observation group received Xihuang capsules combined with medroxyprogesterone acetate for 3 months. The efficacy and survival rates of the two groups were compared. Serum levels of tumor markers [human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), and cytokeratin-19 fragment (CYFRA21-1)] were measured using enzyme-linked immunosorbent assay before and after 3 months of treatment. Immune indicators (CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺) were detected using DxFLEX flow cytometry. The expression levels of oncogenes (c-myc, c-erbB2) and tumor suppressor genes (P16, P53) were determined using PCR. The levels of miR-146a and miR-155 were measured using fluorescence quantitative PCR. Results: The total effective rate in the observation group was significantly higher than that in the control group (65.15% vs 42.42%, χ²=6.858, P=0.009). After treatment, the observation group showed lower levels of HE4, CA125, CEA, and CYFRA21-1 compared to the control group (P<0.05). The observation group also exhibited higher levels of CD4⁺, CD3⁺, CD4⁺/CD8⁺, and miR-146a, and lower levels of CD8⁺ and miR-155 compared to the control group (P<0.05). The expression of c-myc and c-erbB2 was lower, while the expression of P16 and P53 was higher in the observation group compared to the control group (P<0.05). The 1-year and 2-year survival rates in the observation group were 98.41% and 87.30%, respectively, significantly higher than those in the control group (83.61% and 63.93%, respectively) (P<0.05). Conclusion: Xihuang capsules combined with medroxyprogesterone acetate effectively reduce tumor markers, enhance immune function, regulate oncogene expression, and improve survival prognosis in patients with endometrial cancer undergoing chemotherapy, demonstrating significant clinical application value.

Key words： Endometrial cancer Xihuang capsule Medroxyprogesterone acetate Prognosis Therapeutic effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Li
	LI Miaomiao
	LIU Lize

Cite this article:

ZHANG Li,LI Miaomiao,LIU Lize. Effect of Xihuang Capsules Combined with Medroxyprogesterone Acetate on the Prognosis and Related Indicators of Endometrial Cancer Patients Undergoing Chemotherapy[J]. HeBei Med, 2025, 31(4): 691-696.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.04.028 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I4/691

[1] Crosbie EJ,Kitson SJ,McAlpine JN,et al.Endometrial cancer[J].Lancet,2022,399(10333):1412-1428.
[2] Zurcher A,Knabben L,von Gernler M,et al.Depot medroxyprogesterone acetate and breast cancer:a systematic review[J].Arch Gynecol Obstet,2024,309(4):1175-1181.
[3] Cai Yx,Wang B,Xu W,et al.Endometrial cancer:genetic,metabolic characteristics,therapeutic strategies and nanomedicine[J].Curr Med Chem,2021,28(42):8755-8781.
[4] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):501-512.
[5] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[6] Yen TT,Wang TL,Fader AN,et al.Molecular classification and emerging targeted therapy in endometrial cancer[J].Int Gynecol Pathol,2020,39(1):26-35.
[7] 徐凌燕,王丹.醋酸甲羟孕酮联合化疗对子宫内膜癌术后患者的治疗效果[J].癌症进展,2023,21(23):2572-2574,2633.
[8] 王璟,卢有媛,谢明霞,等.基于文献计量分析牛黄类药材及其中成药的研究现状[J].中国中药杂志,2023,48(8):2092-2102.
[9] Liu CS,Chen ZL,Wu SLY,et al.Comparative review of effects of pien tze huang and angong niuhuang pill and their potential on treatment of central nervous system diseases[J].Mini Rev Med Chem,2022,22(18):2350-2360.
[10] 汪爱华,张飞忠,王红英.麝香酮调节SHH介导的自噬对卵巢癌细胞恶性进展的影响[J].天津医药,2024,52(2):142-148.
[11] Batiha GE,Wasef L,Teibo JO,et al.Commiphora myrrh:a phytochemical and pharmacological update[J].Naunyn Schmiedebergs Arch Pharmacol,2023,396(3):405-420.
[12] Vermij L,Smit V,Nout R,et al.Incorporation of molecular characteristics into endometrial cancer management[J].Histopathology,2020,76(1):52-63.
[13] Jamieson A,Vermij L,Kramer CJH,et al.Clinical behavior and molecular landscape of stage I p53-abnormal low-grade endometrioid endometrial carcinomas[J].Clin Cancer Res,2023,1(23):4949-4957.
[14] Drissennek L,Baron C,Brouillet S,et al.Endometrial miRNome profile according to the receptivity status and implantation failure[J].Hum Fertil (Camb),2022,25(2):356-368.